



SciGen Re-Acquires the Rights to the Western European Markets For Sci B Vac

26thth June 2007: Scigen Limited (ASX:SIE) announces that it has re-acquired the rights to the Western European markets for its third generation Hepatitis B Vaccine Sci B Vac™ from Berna Biotech Ltd, a Crucell Company, for an undisclosed amount.

The rights to distribute and market the vaccine was given to Berna Biotech Ltd in 2005 thru a tri-partite agreement between Biotechnology General Ltd (now Ferring), Berna and SciGen as part of SciGen's acquisition of the worldwide rights to manufacture and market Sci B Vac. Berna was the former licensee of BTG for the vaccine in Western Europe.

SciGen's acquisition of the rights to Western Europe, second only to the USA market, will give SciGen the opportunity it seeks to identify, select and appoint a strong partner that has greater coverage, a large and direct sales and marketing organization and can position Sci B Vac effectively thru intensive promotional efforts.

The manufacturing of Sci B Vac in SciGen's wholly owned facility in Rehovot, Israel is proceeding as expected and the first batch of vaccines was successfully produced. SciGen has started its first expansion of its facility, which will result in a three-fold increase capacity. This expansion, which is funded thru a loan granted by its major shareholder Bioton of Poland, is scheduled to be completed by the second quarter of calendar year 2008.

About Sci B Vac™:

Sci B Vac™ is a third generation recombinant hepatitis B Vaccine produced by Chinese Hamster ovary cells. Sci B Vac™ contains immunogenic regions of the three surface proteins of HBV.

Sci B Vac™ is a unique hepatitis B vaccine, which has repeatedly been shown to be highly immunogenic and safe in neonates, children and adults alike.

Worldwide sales of hepatitis B vaccines are estimated to be US\$1.2 billion.

About SciGen:

SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and Biosimilar products, which allow for faster entry into the market, as Biosimilar products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.



SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in clinical development, gaining regulatory approval and bringing products to market.

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with subsidiary companies in the USA, Australia, S. Korea, Hong Kong, Philippines, Vietnam, Israel and India, a Joint Venture in China, commercial partners in Europe and collaborative partners in the USA and the Netherlands

Further information:

| Company – Investor Relations | Company |
|--|--|
| Ms. Maria Arroyan SciGen Australia +61 2 9234 1700 email: mariaaroyan@scigen.com.au | Saul Mashaal Chairman, Founder & CEO SciGen Ltd. + 61 2 9485 1800 +65 9630 5691 (Mobile) |